Last $3.87 USD
Change Today -0.05 / -1.28%
Volume 58.9K
PSDV On Other Exchanges
Symbol
Exchange
NASDAQ GM
OTC US
Stuttgart
Frankfurt
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

psivida corp (PSDV) Snapshot

Open
$3.86
Previous Close
$3.92
Day High
$3.95
Day Low
$3.82
52 Week High
09/3/14 - $4.94
52 Week Low
04/14/14 - $3.26
Market Cap
113.6M
Average Volume 10 Days
86.0K
EPS TTM
$-1.42
Shares Outstanding
29.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PSIVIDA CORP (PSDV)

psivida corp (PSDV) Related Businessweek News

No Related Businessweek News Found

psivida corp (PSDV) Details

pSivida Corp. develops products to deliver drugs and biologics in the United States and the United Kingdom. The company develops its products based on its Durasert and Tethadur drug delivery technologies focusing on the treatment of chronic diseases of the back of the eye. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior uveitis. The company also provides Medidur, an injectable, sustained-release micro-insert designed to treat non-infectious uveitis affecting the posterior segment of the eye, which is in Phase III clinical trial.It has strategic collaborations with Alimera Sciences, Inc.; Pfizer, Inc.; Bausch & Lomb Incorporated; Enigma Therapeutics Limited; and Intrinsiq Materials Cayman Limited. The company was founded in 1987 and is headquartered in Watertown, Massachusetts.

24 Employees
Last Reported Date: 09/11/14
Founded in 1987

psivida corp (PSDV) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $708.6K
Principal Financial & Accounting Officer and ...
Total Annual Compensation: $316.0K
Vice President of Corporate Affairs, General ...
Total Annual Compensation: $433.5K
Compensation as of Fiscal Year 2014.

psivida corp (PSDV) Key Developments

pSivida Corp. ILUVIEN Receives Marketing Authorization in Two More EU Countries

pSivida Corp. announced that Finland and Luxembourg have granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. This brings the total number of EU countries in which ILUVIEN has been approved to 15, with two EU approvals still pending.

pSivida Receives Marketing Authorization in Belgium for ILUVIEN

pSivida Corp. announced that the Belgian Federal Agency for Medicines and Health Products (FAMHP) has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

pSivida Corp. Presents at LD Micro Conference, Dec-03-2014 12:00 PM

pSivida Corp. Presents at LD Micro Conference, Dec-03-2014 12:00 PM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, California, United States. Speakers: Paul Ashton, Chief Executive Officer, President and Executive Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PSDV:US $3.87 USD -0.05

PSDV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $219.26 USD -3.13
Regeneron Pharmaceuticals Inc $416.66 USD +2.02
View Industry Companies
 

Industry Analysis

PSDV

Industry Average

Valuation PSDV Industry Range
Price/Earnings 10.2x
Price/Sales 4.0x
Price/Book 3.2x
Price/Cash Flow 10.4x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PSIVIDA CORP, please visit www.psivida.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.